Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News

Pharma News

HiberCell Receives Fast Track Designation from FDA for First-in-Human Studies of PERK Inhibitor (PERKi) HC-5404-FU
HiberCell Receives Fast Track Designation from FDA for First-in-Human Studies of PERK Inhibitor (PERKi) HC-5404-FU
NEW YORK, Sept.
After Moderna contamination mess, Takeda strikes deal with Japan to supply Novavax COVID-19 vaccines
After Moderna contamination mess, Takeda strikes deal with Japan to supply Novavax COVID-19 vaccines
As Moderna faces questions about contaminants found in its COVID-19 vaccines in Japan, the company’s distribution partner in the country, Takeda, is moving forward on its plans with another COVID va...
Bristol Myers, Pfizer score another win in their Eliquis patent defense, protecting the blockbuster until 2028
Bristol Myers, Pfizer score another win in their Eliquis patent defense, protecting the blockbuster until 2028
As a top-selling drug worldwide, Pfizer and Bristol Myers Squibb’s Eliquis is a major target for generic players looking to steal branded sales.
Roche's Polivy to hit $2.4B as doctors expect 'significant switching' in newly diagnosed lymphoma: analyst
Roche's Polivy to hit $2.4B as doctors expect 'significant switching' in newly diagnosed lymphoma: analyst
Roche Pharmaceuticals CEO Bill Anderson recently pegged lymphoma drug Polivy’s potential expansion into newly diagnosed patients as a multibillion-dollar opportunity.
COVID-19: Immunosuppressant drug, remdesivir mix shows promise
COVID-19: Immunosuppressant drug, remdesivir mix shows promise
Taiwanese researchers have found that combining an existing immunosuppressant drug with the COVID-19 medication remdesivir could suppress the ability of the virus to replicate, and thus could be a pos...
Biden administration unveils $65 billion plan to combat next pandemics after Covid
Biden administration unveils $65 billion plan to combat next pandemics after Covid
The Biden administration laid out Friday a $65 billion plan U.
Dr Reddys Lab gains on deal with Citius Pharma for anti-cancer agent E7777
Dr Reddys Lab gains on deal with Citius Pharma for anti-cancer agent E7777
Dr.
Toripalimab FDA Approval Status
Toripalimab FDA Approval Status
Toripalimab is an anti-PD-1 monoclonal antibody in development for the treatment of nasopharyngeal carcinoma.
FDA Approves Invega Hafyera
FDA Approves Invega Hafyera
TITUSVILLE, N.
Oxycontin Maker Purdue Dissolved, Family to Pay $4.5 Billion in Bankruptcy Settlement
Oxycontin Maker Purdue Dissolved, Family to Pay $4.5 Billion in Bankruptcy Settlement
THURSDAY, Sept.
FDA Approves Zanubrutinib in Adults With Waldenström Macroglobulinemia
FDA Approves Zanubrutinib in Adults With Waldenström Macroglobulinemia
The FDA has approved zanubrutinib (Brukinsa) for the treatment of adults with Waldenström macroglobulinemia (WM), a rare type of lymphoma.
Congress “concerned by apparent anomalies” around FDA’s approval of Aduhelm
Congress “concerned by apparent anomalies” around FDA’s approval of Aduhelm
It has been a tough summer for the US Food and Drug Administration (FDA).
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand